The cardioprotective effect of uridine and uridine-5'-monophosphate: the role of the mitochondrial ATP-dependent potassium channel

Experimental Gerontology
Irina B KrylovaGalina D Mironova

Abstract

The activity of mitochondrial ATP-dependent potassium channel (mitoKATP) of rat heart and liver mitochondria was shown to decrease during aging. This partially explains the increase of risk of ischemia at a mature age since mitoKATP activation provides cardioprotection. We demonstrated that uridine-5'-diphosphate (UDP) possesses the property to activate mitoKATP. At a concentration of 30 microM, it reactivated mitoKATP in mitochondria, and 5-hydroxydecanoate (5-HD) eliminated this effect. In experimental animals, UDP precursors uridine and uridine-5'-monophosphate (UMP) (both 30 mg/kg, administered intravenously 5 min before coronary occlusion) decreased the myocardium ischemic alteration index (1.9 and 3.5 times, respectively) and the T-wave amplitude within 60 min after occlusion. Both effects were inhibited by Glibenclamide (Glib) and 5-HD. UMP and uridine decreased the number of premature ventricular beats 5.6 and 1.9 times and the duration of ventricular tachycardia 9.4 and 4.1 times, respectively. Glib and 5-HD inhibited the anti-arrhythmic parameters, 5-HD being less effective. Uridine and UMP decreased the duration of fibrillation 10.8 and 3.6 times, respectively, and this effect was not abolished by Glib and 5-HD. Thus...Continue Reading

References

Aug 22, 1997·Biochimica Et Biophysica Acta·V Yarov-YarovoyK D Garlid
Nov 14, 1997·Trends in Pharmacological Sciences·C M Anderson, F E Parkinson
Jul 22, 1998·Circulation Research·T SatoE Marbán
Jun 4, 1999·Trends in Pharmacological Sciences·G P Connolly, J A Duley
Apr 11, 2000·Journal of Molecular and Cellular Cardiology·G J Grover, K D Garlid
Mar 6, 2004·Circulation Research·Brian O'Rourke

❮ Previous
Next ❯

Citations

Jan 16, 2009·Bulletin of Experimental Biology and Medicine·G D MironovaL D Lukyanova
Jan 25, 2011·Journal of Bioenergetics and Biomembranes·Luciane C AlbericiHelena C F Oliveira
Oct 24, 2014·Bulletin of Experimental Biology and Medicine·V V Bul'onG D Mironova
Mar 6, 2013·Canadian Journal of Physiology and Pharmacology·Silvia N MiricaDanina M Muntean
Oct 27, 2006·Expert Opinion on Emerging Drugs·Philip B Mitchell, Gin S Malhi
Nov 22, 2011·Experimental Gerontology·Andrew P WojtovichKeith Nehrke
Aug 25, 2015·Journal of Pharmaceutical and Biomedical Analysis·Jueun LeeGeum-Sook Hwang
Jul 3, 2019·Scientific Reports·Ekaterina V RozovaGalina D Mironova
Jan 11, 2017·Journal of Bioenergetics and Biomembranes·Natalya I VenediktovaGalina D Mironova
Feb 9, 2021·Acta Physiologica·Wachira WongtanasarasinNipon Chattipakorn
Jul 25, 2021·International Journal of Molecular Sciences·Xuan WangJunjie Luo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.